Although previous studies have suggested that FGF21 levels are a promising predictive biomarker for tumor progression, no previous study has identified the mechanism underlying the effects of FGF21 on tumor progression in extrahepatic tissues. The gene discussed is FGF21; the disease is neoplasm.